The Vox Markets Podcast With Justin Waite

CEO Andrew Webb of Extruded Pharmaceuticals discusses Amur Minerals reverse takeover, which leads to an exciting transformation into drug delivery. Amur is currently classified as an AIM Rule 15 cash shell. It proposes to acquire 100 per cent. of EPL by way of an RTO under AIM Rule 14. Amur has called a general meeting of the Company in order to approve the proposed RTO, approve a change of name to CRISM Therapeutics, and approve a share consolidation of 1 new ordinary share for every 160 existing ordinary shares. EPL is a UK-based pharmaceutical company which was founded in March 2016. EPL has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed®, EPL's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This ensures that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover